Frontline Rituximab Plus Bendamustine in Waldenström Macroglobulinemia
Outcome data from 222 patients with active Waldenstrom macroglobulinemia who were treated at the Mayo Clinic over 18 years were retrospectively reviewed.
All articles by Lauren Burke
Measuring Patient-Reported Outcomes in Waldenström Macroglobulinemia Patients Receiving Rituximab vs Ibrutinib-Rituximab
Researchers sought to further evaluate data on patient-reported outcomes from the iNNOVATE study.
A New Risk Stratification Model for Patients With Smoldering Multiple Myeloma
Researchers developed a new model for risk stratification in patients with SMM based on updated criteria.
The Influence of Smoking Status on Survival and Relapse in Acute Myeloid Leukemia
Researchers sought to expand upon what is known about smoking status and AML diagnosis and understand more about how smoking affects treatment outcomes.
Luspatercept Reduced RBC Transfusion Dependence in Lower-Risk Patients With Myelodysplastic Syndromes
Findings from the MEDALIST trial revealed a significant reduction in transfusion burden for patients being treated with luspatercept compared with placebo
Brentuximab Vedotin Approved for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-expressing Mycosis Fungoides
The U.S. Food and Drug Administration has approved brentuximab vedotin for the treatment of adult patients with pcALCL or CD30-expressing mycosis fungoides who have received prior systemic therapy.
Next post in Lymphoma
